M3, Inc.
2413.TMEDIUMSatellite · Weight: 7%· Data as of 2026-06-03
Investment Thesis
FY2026 results confirmed re-acceleration thesis: revenue ¥351.4B (+23.3% YoY), OP ¥73.5B (+16.8%), NP ¥49.1B (+21.3%). FY2027 guidance: Revenue ¥400B (+13.8%), OP ¥80B (+8.8%), NP ¥53B. Stock ¥1,474 trades at PE 19.4x trailing / 17.9x forward — cheapest since the -84% drawdown from ATH. Analyst unanimity: 9 buy, 0 sell; average 12M target ¥2,299 (+56% upside). Capital return boost and dividend raised. Core Medical Platform (6.5M doctors, m3.com) still growing. Hybrid hospice/platform model expanding. Caution: Patient Solutions +397% YoY from EWEL acquisition — organic growth likely 12-15% not 23%.
Risk
1) M&A-driven revenue distortion: EWEL acquisition April 2025 inflates headline +23.3%; organic growth ~12-15%. 2) FY2027 guidance decelerating: revenue +13.8% vs FY2026's +23.3% — growth engine slowing. 3) OP margin declining: OP/Revenue = 20.9% (FY2026) vs our old thesis 23.6% — acquisition dilution. 4) Hospice rollup execution risk — physical care facilities have different economics from digital platform. 5) Goldman Sachs downgrade (from original thesis) — monitor if other brokers follow. 6) Forward PE 17.9x modest but not cheap for a decelerating grower.
Monitoring Trigger
If Q1 FY2027 (Jul-Aug 2026) shows organic revenue growth >12% (excluding M&A), HOLD conviction. If Medical Platform segment grows >15% YoY, ADD to 9% — core engine re-accelerating. If another major broker downgrades (2 total), TRIM to 5%. If FY2027 guidance is revised downward at mid-year, EXIT — growth story deteriorating.
Key Dates
Update History
Added supply_chain entries (was empty). 3 entries added: pharma marketing platform, hospital staffing, hospice patient solutions.
HOLD (UPGRADED conviction from weak entry-point thesis to confirmed recovery). FY2026 results: revenue ¥351.4B (+23.3%), OP ¥73.5B (+16.8%). PE 19.4x trailing, 17.9x fwd. Analyst 9 buy / 0 sell, ¥2,299 target (+56% upside). Capital return boost. Risks: M&A revenue distortion, FY2027 deceleration, op margin dilution 23.6→20.9%. Added 4 key_dates (empty before). PE updated 19.1→19.4, fwd PE 23.6→17.9 (stock cheaper).
Key Metrics
Supply Chain Evidence
| Evidence | Customer | Product | Detail |
|---|---|---|---|
| confirmed | Global pharmaceutical companies (Japan + US + EU) | m3.com medical information platform — pharma marketing to 6.5M doctors | Pharma companies pay for promotional access to doctor network; Pharma Solutions is M3's highest-margin segment[source](2026-04-14) |
| confirmed | Japanese hospitals and clinics | medi-job (medical staffing) + carenet (nurse platform) | Medical staffing businesses serve Japanese hospital HR departments; M3 is dominant in Japan doctor-facing digital services[source](2026-04-14) |
| confirmed | Japanese elderly / hospice patients | Hospice / nursing home physical care (Patient Solutions rollup) | M3 patient solutions revenue +397% YoY driven by hospice/nursing M&A acquisitions; building physical aging-society infrastructure[source](2026-04-14) |
Sources & References
Peer Comparison
| Company | PE | Fwd PE | ROE | Op Margin | FCF |
|---|---|---|---|---|---|
| Nihon Kohden Corporation | 20.3 | 18.9 | 7.1% | 7.97% | N/A |
| M3, Inc. | 19.4 | 17.9 | 12.2% | 20.9% | N/A |
| Fukuda Denshi Co., Ltd. | 15.87 | 15.66 | 8.6% | 18.0% | +¥21B |
| JMDC Inc. | 35.85 | 29.06 | 7.8% | 22.3% | +¥9B |
| PHC Holdings Corporation | 38.5 | 10.71 | 0.6% | 6.2% | +¥32B |
| Sysmex Corporation | 22.5 | N/A | N/A | ~20% (est. from EBITDA 25.3%) | N/A |
| Olympus Corporation | 22.98 | N/A | N/A | 18.9% (adj FY2025) | +¥109B (adj FY2025) |